156 related articles for article (PubMed ID: 1567180)
1. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
Chambers AF; Behrend EI; Wilson SM; Denhardt DT
Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
[TBL] [Abstract][Full Text] [Related]
2. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
[TBL] [Abstract][Full Text] [Related]
4. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
[TBL] [Abstract][Full Text] [Related]
5. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin.
Chambers AF; Hota C; Prince CW
Cancer Res; 1993 Feb; 53(3):701-6. PubMed ID: 8425206
[TBL] [Abstract][Full Text] [Related]
6. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
Su ZZ; Austin VN; Zimmer SG; Fisher PB
Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
[TBL] [Abstract][Full Text] [Related]
7. Ras-responsive genes and tumor metastasis.
Chambers AF; Tuck AB
Crit Rev Oncog; 1993; 4(2):95-114. PubMed ID: 8420573
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.
Senger DR; Perruzzi CA; Papadopoulos A
Anticancer Res; 1989; 9(5):1291-9. PubMed ID: 2686530
[TBL] [Abstract][Full Text] [Related]
10. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
11. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
12. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
Xuan JW; Hota C; Shigeyama Y; D'Errico JA; Somerman MJ; Chambers AF
J Cell Biochem; 1995 Apr; 57(4):680-90. PubMed ID: 7542253
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin expression in mammary gland development and tumorigenesis.
Rittling SR; Novick KE
Cell Growth Differ; 1997 Oct; 8(10):1061-9. PubMed ID: 9342184
[TBL] [Abstract][Full Text] [Related]
14. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
Gardner HA; Berse B; Senger DR
Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
[TBL] [Abstract][Full Text] [Related]
15. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
Chang PL; Chambers AF
J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
[TBL] [Abstract][Full Text] [Related]
16. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
Su L; Mukherjee AB; Mukherjee BB
Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli.
Lopez CA; Hoyer JR; Wilson PD; Waterhouse P; Denhardt DT
Lab Invest; 1993 Sep; 69(3):355-63. PubMed ID: 8377476
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene.
Wu Y; Denhardt DT; Rittling SR
Br J Cancer; 2000 Jul; 83(2):156-63. PubMed ID: 10901364
[TBL] [Abstract][Full Text] [Related]
19. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell.
Muschel RJ; Williams JE; Lowy DR; Liotta LA
Am J Pathol; 1985 Oct; 121(1):1-8. PubMed ID: 3901774
[TBL] [Abstract][Full Text] [Related]
20. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
Shanmugam V; Chackalaparampil I; Kundu GC; Mukherjee AB; Mukherjee BB
Biochemistry; 1997 May; 36(19):5729-38. PubMed ID: 9153413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
